Lead Sponsor

Incyte Corporation

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL
•Willingness to avoid pregnancy or fathering children
•In the opinion of the investigator, be able and willing to receive adequate mandatory prophylaxis and/or therapy for thromboembolic events (eg, aspirin 70-325 mg daily or low-molecular-weight heparin)
•Previously treated with at least 1 prior systemic anti-CD20 immunotherapy or chemo-immunotherapy
•Documented relapsed, refractory, or PD after treatment with systemic therapy
•ECOG performance status of 0 to 2

•Women who are pregnant or breastfeeding.
•Any histology other than FL and MZL or clinical evidence of transformed lymphoma
•Prior non-hematologic malignancy
•Congestive heart failure
•HCV positivity, chronic HBV infection or history of HIV infection
•Active systemic infection
•CNS lymphoma involvement
•Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the start of Cycle 1
•Prior use of lenalidomide in combination with rituximab

Related studies

NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more

NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

NCT06337318 · Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features

NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more

NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.